STAFF BOARD
Article
CHAIRMAN
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
MARKETING MANAGER
EDITORIAL BOARD
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 23 - Issue 3, July-September 2021
SPECIAL ARTICLES
DARATUMUMAB/LENALIDOMIDE/ DEXAMETHASONE FOR THE TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WHO ARE INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
CLARAMUNT GARCÍA RAQUEL, SORIA MARTÍN ALBERTO, SÁNCHEZ RUIZ ANDRÉS


The Daratumumab/Lenalidomide/Dexamethasone regimen has recently been approved
by the European Medicines Agency for the treatment of newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplantation. This combination has been studied in the pivotal phase III MAIA trial where participants were assigned to receive Daratumumab/Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone. The progression free survival result favors treatment group, with a HR: 0.56 (95% CI: 0.44-0.71; P <0.0001). According to metanalysis and indirect comparisons, Daratumumab/Lenalidomide/Dexamethasone is comparable in efficacy and safety to existing alternatives for the proposed indication, but it does not provide any improvement in the cost-effectiveness profile.

DARATUMUMAB – EFFICACY – EVALUATION – LENALIDOMIDE – MYELOMA



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25